Enanta Pharmaceuticals Inc
ENTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001177648
No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Enanta Pharmaceuticals Inc changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 145 | 1 | 134 | −10 |
| Shares | 19.9M | 7.08K | 20.2M | +331.1K (+1.7%) |
| Value | $805.3M | $286.3K | $438.4M | −$366.7M (−45.5%) |
1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Acadian Asset Management LLC | 100,581 | $2.15M | 0.01% |
| D. E. Shaw & Co., Inc. | 52,549 | $1.12M | 0.00% |
| AXA S.A. | 31,300 | $669.8K | 0.00% |
| Two Sigma Investments, LP | 29,623 | $633.9K | 0.00% |
| PDT Partners, LLC | 27,619 | $591.0K | 0.08% |
| Walleye Capital LLC | 26,954 | $576.8K | 0.01% |
| XTX Topco Ltd | 11,842 | $253.4K | 0.05% |
| Tudor Investment Corp Et Al | 10,365 | $221.8K | 0.00% |
| Engineers Gate Manager LP | 10,178 | $217.8K | 0.01% |
| Verition Fund Management LLC | 9,956 | $213.1K | 0.00% |
| Aquatic Capital Management LLC | 600 | $13.0K | 0.00% |
| Quantbot Technologies LP | 300 | $6.42K | 0.00% |
| Huntington National Bank | 137 | $2.93K | 0.00% |
| EverSource Wealth Advisors, LLC | 68 | $1.46K | 0.00% |
| Baker Avenue Asset Management, LP | 33 | $706 | 0.00% |
| Parallel Advisors, LLC | 13 | $278 | 0.00% |
| Abound Wealth Management | 7 | $150 | 0.00% |
| Comerica Bank | 785 | $0 | 0.00% |
Sold out (28)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (1)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| ETF Managers Group, LLC | 7,080 | $286.3K |